Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.64 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.64 |
| ▸ | FAP | Q12884 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383434 | 1.00 | DPP4 (0.64) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL488953 | 1.00 | DPP4 (0.64) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL5413834 | 0.98 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10326191 | 0.98 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL3331450 | 0.98 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL3335449 | 0.98 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL14548972 | 0.98 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL3332858 | 0.96 | DPP4 (0.64) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL3332865 | 0.96 | DPP4 (0.64) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL6586024 | 0.94 | DPP4 (0.57) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4806628-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-1620091-A2 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-02-01 | — | — | EP | claimed |
| WO-2004098591-A2 | INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | claimed |
| WO-2024143263-A1 | FLUORESCENCE INTENSITY ENHANCING AGENT, METHOD FOR ENHANCING FLUORESCENCE INTENSITY OF FLUORESCENTLY LABELED TARGET BIOLOGICAL MATERIAL, AND FLUORESCENCE DETECTION KIT | 富士フイルム株式会社 | 2024-07-04 | — | — | WO | disclosed |
| CN-116615417-B | 1, 4-Diheterocyclic group substituted aromatic ring or aromatic heterocyclic compound and application thereof | 广州必贝特医药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-116615417-A | 1, 4-diheterocycle substituted aromatic ring or aromatic heterocyclic compound and application thereof | 广州必贝特医药股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2019-05-09 | — | — | US | disclosed |
| US-9572784-B2 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk | ELCELYX THERAPEUTICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150196509-A1 | Compositions Comprising Statins, Biguanides and Further Agents for Reducing Cardiometabolic Risk | ANJI PHARMACEUTICALS INC. | 2015-07-16 | — | — | US | disclosed |
| CN-104780915-A | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk | ELCELYX THERAPEUTICS INC | 2015-07-15 | — | — | CN | disclosed |
| EP-2872127-A1 | COMPOSITIONS COMPRISING STATINS, BIGUANIDES AND FURTHER AGENTS FOR REDUCING CARDIOMETABOLIC RISK | Elcelyx Therapeutics, Inc. (US) | 2015-05-20 | — | — | EP | disclosed |
| US-6140330-A | USEFUL AS PROTEIN KINASE INHIBITOR; FOR TREATMENT OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, MULTIPLE SCLEROSIS, PSORIASIS, ETC., VARIOUS ALLERGIC DISEASES SUCH AS CROHN'S DISEASE, ASTHMA | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-10-31 | — | — | US | disclosed |
| WO-1999046272-A1 | SERINE PEPTIDASE MODULATORS | FONDATECH BENELUX N.V. (BE) | 1999-09-16 | — | — | WO | disclosed |
| EP-0858452-A1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998004536-A1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1998-02-05 | — | — | WO | disclosed |
| US-4983623-A | Prolyl endopeptidase inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-01-08 | — | — | US | disclosed |
| EP-0156191-B1 | CONDENSED DIAZEPINONES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1989-07-19 | — | — | EP | disclosed |
| EP-0320753-A2 | Derivatives of cyclic aminoacids, their preparation, compounds containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-06-21 | — | — | EP | disclosed |
| US-4550107-A | Condensed diazepinones, their compositions and methods of use as pharmaceuticals | DR. KARL THOMAE GMBH (DE) | 1985-10-29 | — | — | US | disclosed |
| EP-0156191-A2 | Condensed diazepinones, process for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | OPRL1, GRIN2A, GRM1 | DPP4 1954/4885DPP8 2040/4885DPP9 2024/4885 |
| US-20150196509-A1 | Compositions Comprising Statins, Biguanides and Further Agents for Reducing Cardiometabolic Risk | PCSK9, HMGCR, PCSK7 | DPP4 20/4885DPP8 38/4885DPP9 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.